Market Overview

UPDATE: Wedbush Securities Reiterates Outperform Rating, Raises PT on Synageva BioPharma Corp.

Share:
Related GEVA
Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted
Clear Channel Outdoor, Oasis Petroleum And Other Insiders Have Been Buying
Synageva Starts Dosing in Phase I/II Study for Sanfilippo B - Analyst Blog (Zacks)

In a report published Wednesday, Wedbush Securities reiterated its Outperform rating on Synageva BioPharma Corp. (NASDAQ: GEVA), and raised its price target from $42.00 to $50.00.

Wedbush Securities noted, “In an abstract at AALSD, the company reported that in 3 of 7 subjects where MRI data were available, there was a reduction in liver fat fractions, indicating that, in addition to normalization of liver enzymes and lipids, patients could be seeing additional clinical benefit with SBC-102 treatment. We expect updates to these data as they become available at AALSD and LDN (Q1:13).”

Synageva BioPharma Corp. closed on Tuesday at $42.85.

Latest Ratings for GEVA

DateFirmActionFromTo
Oct 2014SunTrust Robinson HumphreyInitiates Coverage onBuy
Jul 2014CitigroupInitiates Coverage onNeutral
Jul 2014JP MorganMaintainsOverweight

View More Analyst Ratings for GEVA
View the Latest Analyst Ratings

Posted-In: Wedbush SecuritiesAnalyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (GEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters